BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PlainTrial//Saved Trials Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PlainTrial saved trials
X-WR-CALDESC:Estimated completion dates for the clinical trials you saved o
 n PlainTrial.
BEGIN:VEVENT
UID:plaintrial-NCT04762641-completion@plaintrial.com
DTSTAMP:20261027T224816Z
DTSTART;VALUE=DATE:20260615
SUMMARY:This is a Study to Evaluate the Safety and Tolerability of ABL503\,
  and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2
  Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced o
 r Metastatic Solid Tumors — estimated completion date
DESCRIPTION:Recruiting. Saved on your PlainTrial shortlist. Full trial reco
 rd: https://plaintrial.com/trial/NCT04762641
URL:https://plaintrial.com/trial/NCT04762641
END:VEVENT
END:VCALENDAR